FDA Approves COSENTYX — Novartis Pharmaceuticals Corporation

# FDA Approves Novartis's Cosentyx (Secukinumab) Intravenous Formulation Novartis Pharmaceuticals Corporation received FDA approval for an intravenous formulation of Cosentyx (secukinumab), expanding the drug's delivery options and potentially broadening its market reach across patient populations seeking alternative administration routes. The approval positions Novartis to capture additional market share in the immunology space by offering clinicians and patients greater flexibility in treatment modalities for inflammatory conditions.